Cell Therapeutics, Inc. (NASDAQ:CTIC)

certitguy (< 20) Submitted: 6/21/2007 6:15:54 PM : Start Price: $17.88 CTIC Score: -86.68

I think the way the FDA is shooting down these new drug discoveries it's a good chance a lot of these pharma companies will either go under or struggle. The FDA is corrupt just like our government, whoever has the most money gets what they need. I own shares and I'm just going to ride the ups and downs until something significant happens.

asemritc (92.78) Submitted: 6/13/2007 11:16:31 AM : Start Price: $20.58 CTIC Score: +88.34

Too much uncertainty

kanstockman (< 20) Submitted: 6/11/2007 2:45:48 PM : Start Price: $21.12 CTIC Score: +87.77

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

molechaser (< 20) Submitted: 4/11/2007 6:38:48 PM : Start Price: $40.08 CTIC Score: -94.89

none

dirt0digger (38.43) Submitted: 4/11/2007 3:49:06 PM : Start Price: $43.44 CTIC Score: -94.93

Extremely positive news on its drug development program

leonard228 (50.30) Submitted: 3/19/2007 9:15:24 AM : Start Price: $38.40 CTIC Score: -97.92

A few very good possibilitys in the pipeline but management seems to be "managing" very well at this juncture. "High risk" but if any of the additional phase III trials pan out, FDA approval will soon follow. Recent new partners will help.

NetscribeHealthC (23.30) Submitted: 3/12/2007 6:39:44 AM : Start Price: $37.20 CTIC Score: -97.41

Cell Therapeutics is focused on developing novel, less-toxic, and more effective, treatments for cancer. It has two late stage pipeline products, Pixantrone and XYOTAX, in Phase III development. Pixantrone is an anthracycline analog being developed for treatment of Non Hodgkins Lymphoma (NHL) and is designed to improve the activity and safety profile of the anthracyclines. XYOTAX is a novel chemotherapeutic that links Paclitaxel to a biodegradable, water soluble polyglutamate polymer, resulting in a new chemically entity, for curing Non Small Cell Lung Cancer (NSCLC) and Ovarian cancer. XYOTAX’ European filing for marketing approval is expected in April 2007.

The quest to cure cancer has been an ongoing pursuit for many decades. Several of the chemotherapy agents and trials have shown initial partial success, but have failed in the long run because of the side effects. Cell Therapeutics is chemically re-engineering existing chemotherapeutic agents such that their side effects are minimized. Its novel Polyglutamate Polymer Technology platform offers improvements in the ease of administration and safety profiles of currently marketed anti-cancer agents.

The company has been able to develop strategic partnerships with Novartis Pharmaceuticals based on its strong technology and promising clinical pipeline. Under the terms of the collaboration, Novartis would participate in commercialization of XYOTAX. If it does so, Novartis will pay future XYOTAX development costs, 50% of retroactive development costs, up to $270 million in sales and regulatory milestones.

For the nine months ended September 2006, Cell Therapeutics' revenues totaled $60,000, down from $14.9 million reflecting absence of product sales due to divestiture of TRISENOX, and fall in license & contract revenue. The company has two promising Phase III pipeline products, each with a multi-hundred million dollar market potential - XYOTAX for NSCLC and Pixantrone for NHL - and a validating collaborative agreement with Novartis in place making it a qualified investment proposition.